The advent of biosimilars: challenges and risks.
Swiss Med Wkly
; 144: w13980, 2014.
Article
em En
| MEDLINE
| ID: mdl-24984255
ABSTRACT
Biosimilars represent a new class of medicinal products that will have significant impact on clinical use. They are identical on an amino acid sequence level to existing reference biopharmaceutical products (originals). However, they may exhibit differences on a protein level. This paper provides a brief overview of biosimilar development and describes the risk and challenges that should be considered during the admission of biosimilars into the clinic.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Conformação Proteica
/
Sequência de Aminoácidos
/
Medicamentos Biossimilares
/
Anticorpos Monoclonais
Tipo de estudo:
Etiology_studies
/
Risk_factors_studies
Limite:
Humans
Idioma:
En
Ano de publicação:
2014
Tipo de documento:
Article